MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

PTC Therapeutics Inc

Chiusa

SettoreSettore sanitario

64.42 1.05

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

63.04

Massimo

65.15

Metriche Chiave

By Trading Economics

Entrata

-931M

-65M

Vendite

-997M

179M

P/E

Media del settore

9.192

37.257

Margine di Profitto

-36.254

Dipendenti

939

EBITDA

-1B

-35M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+3.08% upside

Dividendi

By Dow Jones

Utili prossimi

6 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

1B

5.1B

Apertura precedente

63.37

Chiusura precedente

64.42

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

PTC Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

29 lug 2025, 16:40 UTC

I principali Market Mover

PTC Therapeutics Gains on FDA Approval for Blood-Disorder Treatment

2 dic 2024, 12:47 UTC

I principali Market Mover

PTC Therapeutics Shares Jump on Pact With Novartis

Confronto tra pari

Modifica del prezzo

PTC Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

3.08% in crescita

Previsioni per 12 mesi

Media 65.87 USD  3.08%

Alto 118 USD

Basso 44 USD

Basato su 17 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per PTC Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

17 ratings

11

Acquista

5

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

40.81 / 50.39Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
help-icon Live chat